Drug Type Bispecific antibody |
Synonyms- |
Target |
Action agonists, inhibitors |
Mechanism 4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists), Tumor-associated antigen inhibitors(Tumor-associated antigen inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhaseDiscontinuedPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | China | 01 Feb 2025 |






